Quince Therapeutics, Inc. (QNCX)
Oxford Ledge is still expanding full research coverage of QNCX. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A biotechnology company pursuing strategic alternatives after its lead drug candidate failed to show effectiveness in clinical trials.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K 3.03; Amendments to articles or bylaws; Financial statements and exhibits 2026-06-26
- 8-K Shareholder vote results 2026-06-11
- 8-K Other material event 2026-05-21
- 8-K Entry into material agreement; Completion of acquisition or disposition; 3.02; Departure/election of directors or officers; Amendments to articles or bylaws; Regulation FD disclosure; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-11
Source: SEC EDGAR.
Annual results
5 years of annual figures for QNCX, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$84.0M | -$1.68 |
| 2024 | — | -$56.8M | -$1.31 |
| 2023 | — | -$31.4M | -$0.84 |
| 2022 | — | -$51.7M | -$1.54 |
| 2021 | — | -$89.9M | -$3.03 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for QNCX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open QNCX in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.